Antibody Drug Conjugate Market Size Is Expected to Exhibit 19% CAGR By 2023

Antibody Drug Conjugate Market Outlook

The Global Antibody Drug Conjugate Market size is expected to exhibit 19% CAGR by 2023 (forecast period). It can thrive during the forecast period due to the ability of ADCs to strengthen the immunity system and enhances its ability to fight cancerous cells. Development of novel therapeutic agents to be included in ADCs to fight cancer can drive the market growth. Emergence of targeted therapies and high prevalence of various cancers are other drivers of the market. Increased investment by drug manufacturers and collaboration between biotechnology and biopharmaceutical companies can bolster the market growth.

But soaring production costs due to active pharmaceutical ingredients (APIs) can hamper the market. Antibody drug conjugates (ADCs) are a new class of biopharmaceutical drug containing an antibody with to a biologically active drug. They are designed to eliminate the tumor after being released in the bloodstream to target cancerous cells. The global antibody drug conjugate market report by Market Research Future (MRFR) contains in detail the effects of ADCs as well as the large potential in medical applications.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1113

Antibody Drug Conjugate Market Segmentation Analysis

The antibody drug conjugate market is segmented by type, product, technology, application, and end-user.

By type, The antibody drug conjugate market is segmented into linker, drug/toxin, monoclonal antibodies, and others. The monoclonal antibodies segment is projected to thrive during the forecast period. This can be attributed to successful clinical trials by prominent companies as well as development of other drugs in the pipeline can augur favorably for the segment growth.

By product, the antibody drug conjugate market is segmented into Kadcyla, Adcertis, and others.

By technology, the antibody drug conjugate market is segmented into Immunomedics technology, ImmunoGen technology, Seattle Genetics technology, and others.

By application, the antibody drug conjugate market is segmented into breast cancer, kidney cancer, lymphoma, lung cancer, multiple myeloma, pancreas cancer, prostate cancer, ovary cancer, glioblastoma, leukemia, colon cancer, solid tumors, skin cancer, and others. Breast cancer can be the largest segment during the forecast period due to high incidence of such cancers.

By treatment, the antibody drug conjugate market is segmented into targeted therapy, hormone therapy, radiation therapy, chemotherapy, surgery, and others. Chemotherapy and targeted therapy are segments deemed to gain maximum revenue for the antibody drug conjugate market in the coming years.

By end-user, the antibody drug conjugate market is segmented into hospitals, biopharmaceutical companies, academic research institutes, specialized cancer centers, biotechnology companies, and others.

Antibody Drug Conjugate Market Regional Analysis

Asia Pacific (APAC), the Americas, the Middle East & Africa (MEA), and Europe are regions covered in the global antibody drug conjugate market report.

The Americas is predicted to be the leading region in the market followed by Europe. The region is expected to experience a massive windfall due to implementation of nanotechnology for hosting ADCs, advances in manufacturing processes, and technological breakthroughs. Presence of prominent drug manufacturers combined with approval of drugs are likely to augment the global market revenue manifold.

The APAC region is expected to be one of the biggest regions in the coming years due to heavy investments by biopharmaceutical companies. Furthermore, outsourcing of drug contracts to India and China due to cost-effective labor and skilled personnel can influence the regional antibody drug conjugate market growth.

Antibody Drug Conjugate Market Competitive Outlook

Synthon, Seattle Genetics, Mersana Therapeutics, Concortis Biotherapeutics, Agensys, Inc., Pfizer Inc., AbbVie Inc., ImmunoGen, Inc., Millennium Pharmaceuticals, Roche Holding AG, Antikor, Immunomedics, Heidelberg Pharma, Genentech, Oxford BioTherapeutics, Astellas Pharma/Agensys, Progenics Pharmaceuticals, Bayer HealthCare, Celldex Therapeutics, and others are some of the major players in the antibody drug conjugate market.

Collaborations and partnerships are at an all-time high as evident by the plans of these companies to gain a wider consumer base. Collaborations would assist companies to gain license of drugs and mass produce them effectively in countries with lax regulations and taxes.

Browse More Details at: https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

This release was published on openPR.